MeiraGTx Holdings is a clinical stage gene therapy company with six programs in clinical development and a pipeline of preclinical and research programs. Co.'s focus is on three areas of unmet medical need: ocular diseases, including inherited retinal diseases, as well as large degenerative diseases, severe forms of xerostomia and neurodegenerative diseases. Co.'s product candidates include: AAV-RPGR, which is for the indication of X-linked Retinitis Pigmentosa; AAV-RPE65, which is for the indication of RPE65-Associated Retinal Dystrophy; AAV-CNGB3, which is for the indication of Achromatopsia; and AAV-AIPL1, which is for the indication of Leber congenital amaurosis 4. The MGTX stock yearly return is shown above.
The yearly return on the MGTX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the MGTX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|